PCRX
BEARISH
$23.86
Live
Pacira BioSciences, Inc. · NASDAQ
Target $28.71
(+20.3%)
$18.8
52W Range
$27.64
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 17, 2026
Market cap
$1.03B
P/E
149.12
ROE
1.0%
Profit margin
1.0%
Debt/Equity
0.6
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
PCRX exhibits a stable but mediocre Piotroski F-Score of 4/9, indicating a lack of strong fundamental momentum. The stock is severely overvalued relative to its deterministic baselines, trading at $23.86 despite a Graham Number of $7.79 and an Intrinsic Value of $1.12. While the balance sheet remains liquid with a current ratio of 4.54, the company is facing a crisis in profitability with earnings growth plummeting by 88.40% YoY. The massive discrepancy between the trailing P/E (149.12) and forward P/E (6.83) suggests the market is pricing in a recovery that is not yet supported by current growth metrics or insider activity.
Key Strengths
Strong liquidity position with a Current Ratio of 4.54
Manageable leverage with a Debt/Equity ratio of 0.60
High Gross Margin of 63.24% indicating strong product pricing power
Positive analyst sentiment with a target price of $28.71
Stable Piotroski F-Score (4/9) preventing a 'weak' health classification
Key Risks
Severe earnings collapse with YoY growth at -88.40%
Extreme valuation disconnect from Graham and Intrinsic value baselines
High PEG ratio (11.21) indicating the stock is overpriced relative to growth
Heavy product concentration risk centered on EXPAREL and ZILRETTA
Bearish insider sentiment with 8 sell transactions and 0 buys
AI Fair Value Estimate
Based on comprehensive analysis
$8.5
-64.4% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
24
Weak
15
20
25
60
0
AI Verdict
Overvalued with deteriorating earnings
Key drivers: Earnings collapse, Valuation premium, Insider selling, Product concentration
Confidence
90%
Value
15/100
Ref P/E, PEG, Graham Number
Positives
- Low Price/Book (1.42)
Watchpoints
- Price is 3x the Graham Number
- Trailing P/E is excessive (149.12)
- PEG ratio is extremely high (11.21)
Future
20/100
Ref Growth rates
Positives
- Low Forward P/E (6.83) suggests expected recovery
Watchpoints
- Earnings growth -88.40% YoY
- Revenue growth stagnant at 5.10%
Past
25/100
Ref Historical trends
Positives
- Recent 1-month price recovery (+8.8%)
Watchpoints
- 5-Year change of -62.4%
- Consistent earnings misses in recent quarters
Health
60/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Excellent Current Ratio (4.54)
- Low Debt/Equity (0.60)
Watchpoints
- Piotroski F-Score is only 4/9
- Operating margin is negative (-1.17%)
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend payments
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$23.86
Analyst Target
$28.71
Upside/Downside
+20.3%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for PCRX and closest competitors.
Updated 2026-04-16
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
PCRX
Pacira BioSciences, Inc.
Primary
|
-62.4% | -44.9% | -2.5% | +4.8% | +8.8% | +0.2% |
|
ASTH
Astrana Health, Inc.
Peer
|
-19.7% | -41.8% | -41.4% | -36.4% | -7.6% | +2.4% |
|
KMTS
Kestra Medical Technologies, Ltd.
Peer
|
-18.2% | -18.2% | -26.2% | -18.8% | -19.3% | -9.9% |
|
AKTS
Aktis Oncology, Inc.
Peer
|
-15.2% | -15.2% | -15.2% | -15.2% | +5.2% | +1.0% |
|
PHAT
Phathom Pharmaceuticals, Inc.
Peer
|
-65.2% | +21.0% | +198.5% | -5.3% | +16.2% | -0.2% |
PCR
Pacira BioSciences, Inc.
Primary
5Y
-62.4%
3Y
-44.9%
1Y
-2.5%
6M
+4.8%
1M
+8.8%
1W
+0.2%
AST
Astrana Health, Inc.
Peer
5Y
-19.7%
3Y
-41.8%
1Y
-41.4%
6M
-36.4%
1M
-7.6%
1W
+2.4%
KMT
Kestra Medical Technologies, Ltd.
Peer
5Y
-18.2%
3Y
-18.2%
1Y
-26.2%
6M
-18.8%
1M
-19.3%
1W
-9.9%
AKT
Aktis Oncology, Inc.
Peer
5Y
-15.2%
3Y
-15.2%
1Y
-15.2%
6M
-15.2%
1M
+5.2%
1W
+1.0%
PHA
Phathom Pharmaceuticals, Inc.
Peer
5Y
-65.2%
3Y
+21.0%
1Y
+198.5%
6M
-5.3%
1M
+16.2%
1W
-0.2%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
149.12
Forward P/E
6.83
PEG Ratio
11.21
P/B Ratio
1.42
P/S Ratio
1.41
EV/Revenue
1.58
EV/EBITDA
9.22
Market Cap
$1.03B
Profitability
Profit margins and return metrics
Profit Margin
0.97%
Operating Margin
-1.17%
Gross Margin
63.24%
ROE
0.96%
ROA
1.48%
Growth
Revenue and earnings growth rates
Revenue Growth
+5.1%
Earnings Growth
-88.4%
Q/Q Revenue Growth
+5.14%
Q/Q Earnings Growth
-89.8%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.6
Moderate
Current Ratio
4.54
Strong
Quick Ratio
3.01
Excellent
Cash/Share
$5.89
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.2B
Gross Margin
79.5%
Op. Margin
1.6%
Net Margin
0.8%
Total Assets
$1.3B
Liabilities
$0.6B
Equity
$0.7B
Debt/Equity
0.82x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-30
$N/A
2026-02-26
$0.57
-37.0% surprise
2025-11-06
$0.7
+7.4% surprise
2025-08-05
$0.74
+4.2% surprise
Healthcare Sector Comparison
Comparing PCRX against 393 companies in the Healthcare sector
(24 bullish, 129 neutral, 240 bearish)
P/E Ratio
149.12
This Stock
vs
90.61
Sector Avg
+64.6%
(Expensive)
Return on Equity (ROE)
0.96%
This Stock
vs
-101.52%
Sector Avg
-100.9%
(Below Avg)
Profit Margin
0.97%
This Stock
vs
-12.47%
Sector Avg
-107.8%
(Weaker)
Debt to Equity
0.6
This Stock
vs
3.4
Sector Avg
-82.3%
(Less Debt)
Revenue Growth
5.1%
This Stock
vs
124.21%
Sector Avg
-95.9%
(Slower)
Current Ratio
4.54
This Stock
vs
4.56
Sector Avg
-0.3%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
PCRX
Pacira BioSciences, Inc.
|
BEARISH | $1.03B | 149.12 | 1.0% | 1.0% | $23.86 | |
|
ASTH
Astrana Health, Inc.
|
BEARISH | $1.02B | 107.0 | 1.8% | 0.3% | $20.33 | Compare |
|
KMTS
Kestra Medical Technologies, Ltd.
|
BEARISH | $1.04B | - | -92.7% | -173.0% | $17.87 | Compare |
|
AKTS
Aktis Oncology, Inc.
|
BEARISH | $1.05B | - | -26.5% | -% | $18.99 | Compare |
|
PHAT
Phathom Pharmaceuticals, Inc.
|
BULLISH | $1.0B | - | -% | -126.3% | $12.61 | Compare |
PCRX
Pacira BioSciences, Inc.
BEARISH
Mkt Cap
$1.0B
P/E
149.1
ROE
1.0%
Price
$23.86
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-17 | FROIMSON MARK | Director | Sale | 500 | $10,905 |
| 2026-03-17 | SLONIN JONATHAN | Officer | Sale | 3,261 | $74,416 |
| 2026-02-11 | RIKER LAUREN BULLARO | Officer | Stock Award | 19,273 | - |
| 2026-02-11 | WILLIAMS KRISTEN MARIE | Officer | Stock Award | 54,546 | - |
| 2026-02-11 | CROSS SHAWN M. | Chief Financial Officer | Stock Award | 49,091 | - |
| 2026-02-11 | LEE FRANK DON | Chief Executive Officer | Stock Award | 261,818 | - |
| 2026-02-11 | SLONIN JONATHAN | Officer | Stock Award | 54,546 | - |
| 2026-02-11 | TEEHAN BRENDAN | Officer | Stock Award | 51,714 | - |
| 2026-02-02 | RIKER LAUREN BULLARO | Officer | Sale | 4,000 | $83,240 |
| 2026-02-02 | WILLIAMS KRISTEN MARIE | Officer | Sale | 13,137 | $269,703 |
| 2026-01-05 | RIKER LAUREN BULLARO | Officer | Sale | 1,416 | $34,324 |
| 2025-12-31 | TEEHAN BRENDAN | Officer | Stock Award | 402 | $10,411 |
| 2025-12-10 | CROSS SHAWN M. | Chief Financial Officer | Sale | 25,000 | $626,751 |
| 2025-12-10 | CROSS SHAWN M. | Chief Financial Officer | Option Exercise | 25,000 | $411,250 |
| 2025-11-17 | SLONIN JONATHAN | Officer | Sale | 3,960 | $95,396 |
FROIMSON MARK
Director
2026-03-17
500 shares
·
$10,905
SLONIN JONATHAN
Officer
2026-03-17
3,261 shares
·
$74,416
RIKER LAUREN BULLARO
Officer
2026-02-11
19,273 shares
WILLIAMS KRISTEN MARIE
Officer
2026-02-11
54,546 shares
CROSS SHAWN M.
Chief Financial Officer
2026-02-11
49,091 shares
LEE FRANK DON
Chief Executive Officer
2026-02-11
261,818 shares
SLONIN JONATHAN
Officer
2026-02-11
54,546 shares
TEEHAN BRENDAN
Officer
2026-02-11
51,714 shares
RIKER LAUREN BULLARO
Officer
2026-02-02
4,000 shares
·
$83,240
WILLIAMS KRISTEN MARIE
Officer
2026-02-02
13,137 shares
·
$269,703
RIKER LAUREN BULLARO
Officer
2026-01-05
1,416 shares
·
$34,324
TEEHAN BRENDAN
Officer
2025-12-31
402 shares
·
$10,411
CROSS SHAWN M.
Chief Financial Officer
2025-12-10
25,000 shares
·
$626,751
CROSS SHAWN M.
Chief Financial Officer
2025-12-10
25,000 shares
·
$411,250
SLONIN JONATHAN
Officer
2025-11-17
3,960 shares
·
$95,396
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
8-K
10-K
PCRX's financial success is primarily dependent on the successful commercialization of EXPAREL and ZILRETTA. Key risks include potential challenges securing adequate third-party payer reimbursement, intense competition from other pharmaceutical and biotechnology companies, and a heavy reliance on third parties for essential services.
8-K
10-Q
8-K
10-Q
8-K
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
7 analysts
Barclays
2026-03-26
Equal-Weight
Equal-Weight
HC Wainwright & Co.
2026-01-09
Buy
Buy
Needham
2026-01-09
Buy
Buy
Barclays
2025-12-09
Equal-Weight
Truist Securities
2025-11-07
Buy
Buy
Past News Coverage
Recent headlines mentioning PCRX from our newsroom.
Newest → oldest
No matching news yet.